Search Results

Alligator Bioscience announced the publication of positive Phase 2 data on its lead drug candidate mitazalimab in first line metastatic pancreatic cancer in The Lancet Oncology.

Alligator Bioscience (STO:ATORX) today announced that two clinical abstracts on its lead drug candidate mitazalimab, a best-in-class CD40 agonist, in first line metastatic pancreatic cancer will be presented (abstracts 2569 and 4133) in a poster presentation session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL and online during May 31-June 4.

Alligator Bioscience AB and Aptevo Therapeutics today announced positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors likely to express the tumor antigen 5T4.

Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics (“Aptevo”) (NASDAQ:APVO) today announced the dosing of the first patient in the companies’ Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4.

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that Company has received a final delisting notice from Nasdaq.

Alligator Bioscience Alligator Bioscience, announces the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer.

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Genflow Biosciences Strengthens Pre-Clinical Efforts with FDA Guidance and CDMO and CRO Selection

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), wishes to announce that

Solid Biosciences Inc. announced that the Company has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of US equity markets, Monday, July 1st 2024.